Health Condition 1: B078- Other viral warts
Conditions
Interventions
Intervention1: Intralesional quadrivalent HPV vaccine: Quadrivalent HPV vaccine will be injected into the lesions at week 0, 4 and 12 weeks
Control Intervention1: Intramuscular HPV vaccine: Intramuscu
Sponsors
Dr s.n medical college
Eligibility
Inclusion criteria
Inclusion criteria: Patient of all genders >8 years Signed informed consent form Confirmed clinical diagnosis of genital condylomata
Exclusion criteria
Exclusion criteria: Individuals who are pregnant or are planning to become pregnant Participant allergic to yeast and vaccine components Patient who have received prior human papilloma virus vaccine Subjects who are immunocompromised or are on immunosuppressive medications or on immunomodulatory agents will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in wart number between week 0 and week 12 Change in mean size of genital condyloma between week 0 and week 12Timepoint: Changes in wart number between week 0 and week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in score of specific questionnaire for condyloma accuminata (CECA) Change in score of dermatology quality of life index (DLQI)Timepoint: Week 0 and Week 12 | — |
Countries
India
Contacts
Public ContactManju Lata Verma
Dr S.N medical College jodhpur
Outcome results
None listed